Here’s What the Research Actually Shows

Chemotherapy-induced peripheral neuropathy, or CIPN, is one of the most common and stubborn side effects of cancer treatment. It affects up to 70% of patients who receive neurotoxic drugs like taxanes and platinum-based chemotherapies, producing tingling, numbness, burning pain, and muscle weakness in the hands and feet. For many survivors, it lingers for years after treatment ends, and there is still no approved drug that reliably prevents or reverses it.

That gap is why a new psilocybin trial at MD Anderson Cancer Center has drawn attention. But it’s worth being precise about what this research is actually testing, because the popular framing of “psilocybin repairs nerve damage” runs ahead of the evidence. Here’s what’s real, what’s hypothesized, and what’s still unknown.

The MD Anderson trial: NeuroGuard

The study in question is a Phase 2 trial called NeuroGuard (ClinicalTrials.gov identifier NCT07227909), sponsored by MD Anderson Cancer Center with the Usona Institute as a collaborator, and led by principal investigator Dr. Moran Amit. It is designed to test whether psilocybin can prevent or reduce the severity of CIPN in patients about to start neurotoxic chemotherapy for breast, colorectal, or head and neck cancer.

The trial has three arms. In Arm A, participants receive two supervised oral doses of psilocybin a week apart before their first chemotherapy cycle, followed by two more supervised doses before cycles two and three. Arm B tests a “subperceptual” microdosing regimen, with low 1 mg doses taken every other day for two weeks before chemotherapy starts. Arm C is standard of care with no study drug, serving as the comparison group. The primary outcome is the proportion of participants whose CIPN symptoms worsen by 12 weeks, measured using the EORTC QLQ-CIPN20 sensory subscale, a validated patient-reported symptom questionnaire.

Two things are important to flag. First, this trial is aimed at prevention and symptom mitigation, not at reversing or “repairing” nerves that are already damaged. Second, as of this writing the trial has not yet reported results. It is a prospective study designed to generate evidence, not a completed study that has already shown psilocybin works for this purpose.

Why researchers think psilocybin might help

The rationale behind NeuroGuard draws on a few separate lines of research, none of which directly show peripheral nerve regeneration in humans, but which together make a plausible case for testing it.

The first line is preclinical work on psilocybin and pain. A 2025 study in Nature Neuroscience found that a single dose of psilocybin produced a rapid and long-lasting reduction in pain-like behavior in mice with nerve injury and inflammatory pain, an effect the researchers linked to activity in specific brain circuits rather than to any local effect at the injured nerve itself. A related study in the British Journal of Pharmacology reported similar findings: a single psilocybin dose led to prolonged reductions in pain behavior in a mouse model of neuropathy. Other preclinical work, summarized in an IUPHAR-affiliated review, ties these effects to activation of the serotonin 5-HT2A receptor, the same receptor responsible for psilocybin’s psychoactive effects. Penn Medicine’s research communications team summarized this body of work as psilocybin “targeting brain circuits” involved in pain processing, which is a meaningfully different mechanism than repairing damaged axons or myelin.

The second line is broader neuroplasticity research. A widely cited 2018 paper by David Olson and colleagues coined the term “psychoplastogen” to describe how psychedelics like psilocybin promote dendritic growth and new synaptic connections, initially observed in rodent cortical neurons. More recent work, including a 2025 eLife study using human iPSC-derived cortical neurons, extends this to human brain cells in a dish. This research supports the idea that psilocybin can promote structural plasticity in the central nervous system. It does not show that psilocybin regenerates injured peripheral sensory nerves in the hands and feet, which is a distinct biological process governed by different cell types (Schwann cells, dorsal root ganglion neurons) than the cortical plasticity these studies examine.

The third line is early clinical signal in adjacent conditions. A systematic review published in Regional Anesthesia & Pain Medicine found that across the studies it examined, 57% showed statistically significant reductions in chronic neuropathic pain symptoms after psilocybin therapy, though the review covered a small and heterogeneous set of studies. A separate trial has examined psilocybin-assisted therapy in patients with advanced cancer, finding improvements in quality of life, pain control, and anxiety, though this population was not selected for CIPN specifically. A preference-assessment study called PEACE-PAIN has also been conducted to gauge patient interest in psilocybin for chronic neuropathic pain ahead of a planned efficacy trial.

What this research does not show

It’s worth being explicit about the gap between the headlines and the data. No published human study has demonstrated that psilocybin repairs structural damage to peripheral nerves, such as regenerating axons or restoring myelin, in people with CIPN or any other form of peripheral neuropathy. The strongest mechanistic evidence so far points to central nervous system effects: altered pain processing in the brain and increased plasticity in cortical neurons. Whether those central effects translate into meaningful, durable relief of CIPN symptoms, let alone actual nerve repair, is precisely the question NeuroGuard and similar trials are designed to answer. It hasn’t been answered yet.

There’s also a regulatory backdrop worth noting. In early 2025, the FDA released draft guidance specifically addressing prevention and treatment of CIPN in drug development, reflecting how difficult this condition has been to target: symptoms are subjective and hard to standardize, the underlying biology involves multiple overlapping injury mechanisms, and because CIPN is a quality-of-life issue rather than immediately life-threatening, drug developers have historically been cautious about adding new agents that could interact with chemotherapy regimens.

The bottom line

MD Anderson’s NeuroGuard trial is a legitimate, actively-designed Phase 2 study testing whether psilocybin, given around the time of chemotherapy, can prevent or reduce CIPN symptoms. It’s grounded in real preclinical findings about psilocybin’s effects on pain circuits and neural plasticity. But it is testing a hypothesis, not confirming one, and the underlying science so far describes changes in brain pain processing and cortical plasticity, not regeneration of damaged peripheral nerves. Anyone encountering claims that psilocybin has been “shown” to repair chemo-induced nerve damage should treat that as a significant overstatement of where the evidence currently stands. The honest version of the story is that this is a promising, well-motivated line of inquiry with results still to come.

References

1. NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy. ClinicalTrials.gov, Study NCT07227909. https://clinicaltrials.gov/study/NCT07227909
2. Psilocybin for Neuropathy — Phase 2 Clinical Trial overview (MD Anderson Cancer Center, PI Moran Amit, MD). Power. https://www.withpower.com/trial/phase-2-psilocybin-4-2026-40959
3. Single-dose psilocybin rapidly and sustainably relieves chronic pain-like behavior via brain circuit effects. Nature Neuroscience (2025). https://www.nature.com/articles/s41593-025-02068-0
4. Askey, T. et al. Psilocybin as a novel treatment for chronic pain. British Journal of Pharmacology. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.17420
5. Psilocybin induces long-lasting effects via 5-HT2A receptor activation in mouse models of pain. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12107474/
6. Psilocybin targets brain circuits to relieve pain. Penn Medicine News. https://www.pennmedicine.org/news/psilocybin-targets-brain-circuits-to-relieve-pain
7. Olson, D. E. Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics. ACS Pharmacology & Translational Science (2018), reviewed via SAGE Journals. https://journals.sagepub.com/doi/10.1177/1179069518800508
8. Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons. eLife (2025). https://elifesciences.org/articles/104006
9. Investigating the therapeutic efficacy of psilocybin in advanced cancer. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271737/
10. Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552286/
11. Psilocybin and chronic neuropathic pain: a systematic review. Regional Anesthesia & Pain Medicine. https://rapm.bmj.com/content/50/11/845
12. Chemotherapy induced peripheral neuropathy research is on the rise. The Foundation for Peripheral Neuropathy (Oct. 2025). https://www.foundationforpn.org/chemotherapy-induced-peripheral-neuropathy-research-is-on-the-rise/
13. FDA draft guidance: Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy — Developing Drug and Biological Products (2025). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/prevention-and-treatment-chemotherapy-induced-peripheral-neuropathy-developing-drug-and-biological